Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Waldenström's macroglobulinemia Stories

2014-02-28 23:27:26

Mayo Clinic researchers say the identification of a mutated gene frequently found in Non-Hodgkin’s Lymphoma may open the door to new treatments. Raleigh, NC (PRWEB) February 28, 2014 A new report published in Blood Cancer Journal and detailed by the Non-Hodgkin’s Lymphoma Center finds that a high percentage of patients with Non-Hodgkin’s Lymphoma have a mutation on their MYD88 gene (MYD88L265P), which in turn can affect their immune system B-cells. B-cells or T-cells are the cells...

2013-12-10 16:25:09

-- Clinical Presentation in Waldenstrom's Macroglobulinemia Deemed "Best of ASH" -- NEW ORLEANS, Dec. 10, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced results of 40 clinical, non-clinical and pre-clinical presentations on ibrutinib (IMBRUVICA((TM))) at the 55(TH) Annual meeting of the American Society of Hematology (ASH) held in New Orleans, Dec 7 - 10, 2013. There were seven presentations of clinical data, of which five were oral presentations, including...

2013-11-13 16:26:31

Ibrutinib becomes second drug with 'breakthrough therapy designation' approved by FDA WHITE PLAINS, N.Y., Nov. 13, 2013 /PRNewswire/ -- Today's U.S. Food and Drug Administration (FDA) approval of ibrutinib to treat patients with mantle cell lymphoma (MCL) is a significant advance for patients with this blood cancer. It was approved as a single agent for treatment of patients with MCL who have received at least one prior therapy. Ibrutinib is the second drug with "breakthrough...

2013-06-20 16:27:14

SUNNYVALE, Calif., June 20, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced results of a study evaluating ibrutinib, an investigational oral Bruton's tyrosine kinase (BTK) inhibitor in patients with Waldenstrom's Macroglobulinemia (WM). Pharmacyclics is jointly developing ibrutinib with Janssen Research & Development, LLC. The data were presented today at the International Conference on Malignant Lymphoma (ICML), taking place in Lugano,...

2013-06-20 00:21:44

SUNNYVALE, Calif., June 19, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced that The New England Journal of Medicine (NEJM) published results of a Phase 2 study evaluating the investigational oral Bruton's tyrosine kinase (BTK) inhibitor ibrutinib in patients with relapsed/refractory mantle cell lymphoma (MCL) online. These data suggested ibrutinib may be effective and generally well-tolerated in patients with relapsed/refractory MCL. Results of a...

2013-06-19 16:26:56

A second study in relapsed/refractory chronic lymphocytic leukemia (CLL) also published in the online edition RARITAN, N.J., June 19, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced that a study published online in The New England Journal of Medicine (NEJM) demonstrates treatment with ibrutinib, an investigational oral Bruton's tyrosine kinase (BTK) inhibitor, resulted in an overall response rate of 68%, with 47% of patients achieving a partial...

2013-06-16 08:20:30

SUNNYVALE, Calif., June 16, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced the results of two separate Phase 2 studies suggesting that ibrutinib, an investigational oral Bruton's tyrosine kinase (BTK) inhibitor, showed efficacy when used as a monotherapy in patients with relapsed/refractory mantle cell lymphoma (MCL) or diffuse large B-cell lymphoma (DLBCL). Pharmacyclics sponsored both studies and is jointly developing ibrutinib with Janssen Research...

2013-04-11 08:28:19

SUNNYVALE, Calif., April 11, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that the Phase III clinical trial (RESONATE(TM)-2), a monotherapy trial using ibrutinib versus chlorambucil in elderly patients with newly diagnosed chronic lymphocytic leukemia / small lymphocyctic lymphoma (CLL/SLL) has enrolled its fifth patient. The enrollment of the fifth patient has subsequently triggered a fourth $50 million milestone payment obligation from Janssen Biotech, Inc., one...

2013-04-08 12:28:38

-Nine Ibrutinib Presentations at the American Association of Cancer Research - SUNNYVALE, Calif., April 8, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to...

2013-02-12 20:21:22

RARITAN, N.J., Feb. 12, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen), today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designations for the investigational oral agent ibrutinib as a monotherapy for two B-cell malignancies: in patients with relapsed or refractory mantle cell lymphoma (MCL) who have received prior therapy, and in patients with Waldenstrom's macroglobulinemia (WM). Enacted as part of the 2012 FDA Safety and...